Abstract
Recombinant adeno-associated virus (AAV) -based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis. This review summarizes manufacturing and characterization of ‘AAV2-hRPE65v2’, the vector used in one completed Phase I/II clinical trial. Regulatory challenges and strategies that were successfully used for this groundbreaking trial are described.
Keywords: AAV vectors, regulatory affairs, cGMP, Leber Congenital Amaurosis, AAV2-hRPE65v2, LCA, Adeno associated virus, RPE65, gene therapy, electroretinograms, alpha1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, Hemophilia B, HIV infection, Parkinson's disease, muscular dystrophy, prostate cancer, malignant melanoma, HEPA, cation exchange column chromatography, HEK293, CRUDE CELL HARVEST, ampicillin, reverse transcriptase Q-PCR, Column chromatography
Current Gene Therapy
Title: Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Volume: 10 Issue: 5
Author(s): J. Fraser Wright, Jennifer Wellman and Katherine A. High
Affiliation:
Keywords: AAV vectors, regulatory affairs, cGMP, Leber Congenital Amaurosis, AAV2-hRPE65v2, LCA, Adeno associated virus, RPE65, gene therapy, electroretinograms, alpha1-antitryspin deficiency, Alzheimer's disease, arthritis, Batten's disease, Canavan's disease, cystic fibrosis, Hemophilia B, HIV infection, Parkinson's disease, muscular dystrophy, prostate cancer, malignant melanoma, HEPA, cation exchange column chromatography, HEK293, CRUDE CELL HARVEST, ampicillin, reverse transcriptase Q-PCR, Column chromatography
Abstract: Recombinant adeno-associated virus (AAV) -based vectors expressing therapeutic gene products have shown great promise for human gene therapy. A recent milestone has been the safety and efficacy observed using recombinant AAV2 expressing retinal pigment epithelial associated 65KDa protein for Leber Congenital Amaurosis. This review summarizes manufacturing and characterization of ‘AAV2-hRPE65v2’, the vector used in one completed Phase I/II clinical trial. Regulatory challenges and strategies that were successfully used for this groundbreaking trial are described.
Export Options
About this article
Cite this article as:
Fraser Wright J., Wellman Jennifer and High A. Katherine, Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65, Current Gene Therapy 2010; 10 (5) . https://dx.doi.org/10.2174/156652310793180715
DOI https://dx.doi.org/10.2174/156652310793180715 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
Reviews on Recent Clinical Trials The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science Smoking and Eye Pathologies. A Systemic Review. Part I. Anterior Eye Segment Pathologies
Current Pharmaceutical Design Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors
Combinatorial Chemistry & High Throughput Screening Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Adverse Drug Reaction Labelling for Atomoxetine, Methylphenidate and Modafinil: Comparison of Product Information for Oral Formulations in Australia, Denmark and the United States
Current Drug Safety The Contrast Sensitivity Test in Early Detection of Ocular Changes in the Relation to the Type I Diabetes Mellitus Compensation in Children,Teenagers, and Young Adults
Recent Patents on Inflammation & Allergy Drug Discovery Current Ocular Drug Delivery Challenges for N-acetylcarnosine: Novel Patented Routes and Modes of Delivery, Design for Enhancement of Therapeutic Activity and Drug Delivery Relationships
Recent Patents on Drug Delivery & Formulation Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers
Current Drug Targets Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Signaling with Homeoprotein Transcription Factors in Development and Throughout Adulthood
Current Genomics The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) with Kangaroo Mother Care (KMC): Comprehensive Care for Preterm Infants
Current Women`s Health Reviews Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges
CNS & Neurological Disorders - Drug Targets Review of Pediatric Uveitis
Current Pediatric Reviews Non-Antidepressant Treatment of Generalized Anxiety Disorder
Current Clinical Pharmacology State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases
Current Clinical Pharmacology Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Genetic Basis of Mitochondrial Optic Neuropathies
Current Molecular Medicine